Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Bevacizumab and XELOX in First-line mCRC
NCT07025239Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing QL1706 + Beva + XELOX with Placebo + Beva + XELOX (2 arms). Primary endpoint: Progression Free Survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07025239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025239.